Find information on thousands of medical conditions and prescription drugs.

Short QT syndrome

Short QT syndrome is a genetic disease of the electrical system of the heart. It consists of a constellation of signs and symptoms, consisting of a short QT interval interval on EKG (≤ 300 ms) that doesn't significantly change with heart rate, tall and peaked T waves, and a structurally normal heart. Short QT syndrome appears to be inherited in an autosomal dominant pattern, and a few affected families have been identified. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
Sabinas brittle hair...
Saccharopinuria
Sacral agenesis
Saethre-Chotzen syndrome
Salla disease
Salmonellosis
Sandhoff disease
Sanfilippo syndrome
Sarcoidosis
Say Meyer syndrome
Scabies
Scabiophobia
Scarlet fever
Schamberg disease...
Schistosomiasis
Schizencephaly
Schizophrenia
Schmitt Gillenwater Kelly...
Sciatica
Scimitar syndrome
Sciophobia
Scleroderma
Scrapie
Scurvy
Selachophobia
Selective mutism
Seminoma
Sensorineural hearing loss
Seplophobia
Sepsis
Septo-optic dysplasia
Serum sickness
Severe acute respiratory...
Severe combined...
Sezary syndrome
Sheehan syndrome
Shigellosis
Shingles
Shock
Short bowel syndrome
Short QT syndrome
Shprintzen syndrome
Shulman-Upshaw syndrome
Shwachman syndrome
Shwachman-Diamond syndrome
Shy-Drager syndrome
Sialidosis
Sickle-cell disease
Sickle-cell disease
Sickle-cell disease
Siderosis
Silicosis
Silver-Russell dwarfism
Sipple syndrome
Sirenomelia
Sjogren's syndrome
Sly syndrome
Smallpox
Smith-Magenis Syndrome
Sociophobia
Soft tissue sarcoma
Somniphobia
Sotos syndrome
Spasmodic dysphonia
Spasmodic torticollis
Spherocytosis
Sphingolipidosis
Spinal cord injury
Spinal muscular atrophy
Spinal shock
Spinal stenosis
Spinocerebellar ataxia
Splenic-flexure syndrome
Splenomegaly
Spondylitis
Spondyloepiphyseal...
Spondylometaphyseal...
Sporotrichosis
Squamous cell carcinoma
St. Anthony's fire
Stein-Leventhal syndrome
Stevens-Johnson syndrome
Stickler syndrome
Stiff man syndrome
Still's disease
Stomach cancer
Stomatitis
Strabismus
Strep throat
Strongyloidiasis
Strumpell-lorrain disease
Sturge-Weber syndrome
Subacute sclerosing...
Sudden infant death syndrome
Sugarman syndrome
Sweet syndrome
Swimmer's ear
Swyer syndrome
Sydenham's chorea
Syncope
Syndactyly
Syndrome X
Synovial osteochondromatosis
Synovial sarcoma
Synovitis
Syphilis
Syringomas
Syringomyelia
Systemic carnitine...
Systemic lupus erythematosus
Systemic mastocytosis
Systemic sclerosis
T
U
V
W
X
Y
Z
Medicines

Symptoms and signs

Individuals with short QT syndrome frequently complain of palpitations and may have syncope (loss of consciousness) that is unexplained. Due to the autosomal dominant inheritance pattern, most individuals will have family members with a history of unexplained or sudden death at a young age (even in infancy), palpitations, or atrial fibrillation.

Short QT syndrome is associated with an increased risk of sudden cardiac death, most likely due to ventricular fibrillation.

Diagnosis

The diagnosis of short QT syndrome consists of characteristic history and findings on EKG and electrophysiologic testing. There are currently no set guidelines for the diagnosis of short QT syndrome.

Electrocardiogam

The characteristic findings of short QT syndrome on EKG are a short QT interval, typically ≤ 300 ms, that doesn't significantly change with the heart rate. Tall, peaked T waves may also be noted. Individuals may also have an underlying atrial rhythm of atrial fibrillation.

Electrophysiologic Studies

In the electrophysiology lab, individuals with short QT syndrome are noted to have short refractory periods, both in the atria as well as in the ventricles. Also, ventricular fibrillation is frequently induced on programmed stimulation.

Etiology

The etiology of short QT syndrome is unclear at this time. A current hypothesis is that short QT syndrome is due to increased activity of outward potassium currents in phase 2 and 3 of the cardiac action potential. This would cause a shortening of the plateau phase of the action potential (phase 2), causing a shortening of the overall action potential, leading to an overall shortening of refractory periods and the QT interval.

In the families afflicted by short QT syndrome, two different missense mutations have been described in the human ether-a-go-go gene (HERG). These mutations result in expression of the same amino acid change in the cardiac IKr ion channel. This mutated IKr has increased activity compared to the normal ion channel, and would theoretically explain the above hypothesis.

Treatment

Currently, the only effective treatment option for individuals with short QT syndrome is implantation of an implantable cardioverter-defibrillator (ICD).

A recent study has suggested that the use of certain antiarrhythmic agents, particularly quinidine, may be of benefit in individuals with short QT syndrome due to their effects on prolonging the action potential and by their action on the IK channels1. While the use of these agents alone is not indicated at present, there may be benefit of adding these agents to individuals who have already had ICD implantation to reduce the number of arrhythmic events.

Read more at Wikipedia.org


[List your site here Free!]


Prolonged treatment with almitrine for refractory hypoxemia in adult respiratory distress syndrome
From CHEST, 5/1/94 by Jean-Benoit Thorens

A 49-year-old man presented with an atypical pneumonia entailing an adult respiratory distress syndrome (ARDS). The refractory hypoxemia caused a myocardial infarction, leading us to try pharmacologic treatments. Almitrine bismesilate (AB) infusion allowed improvement of arterial oxygenation during 115 h without adverse effect. This case is, to our knowledge, the first reported prolonged treatment using AB for hypoxemia due to ARDS.

Almitrine bismesilate (AB) increases [PaO.sub.2] and decreases [PaCO.sub.2] in patients with COPD.[1-3] The AB has also been assessed in patients with the adult respiratory distress syndrome (ARDS).[4-6] It entails a transient but significant improvement in [PaO.sub.2] and in the alveolar-arterial [PO.sub.2] difference,[4] a reduction in ventilation/perfusion inequalities as measured by the multiple inert gas elimination technique,[5] and an increase in [PaO.sub.2] comparable with that of a PEEP of 10 cm [H.sub.2]O.[6] The major side effects of AB are an increase in pulmonary arterial pressure[7] and a peripheral neuropathy during long-term administration.[1]

We report on a patient with ARDS, due to atypical pneumonia, presenting with severe refractory hypoxemia having caused a myocardial infarction, in whom a treatment of AB allowed a prolonged and reproducible improvement of arterial oxygenation without any apparent adverse effects.

CASE REPORT

A 49-year-old male teacher was admitted to the ICU for respiratory failure. His medical history revealed a coronary arterial bypass 5 years previously, without subsequent symptoms. He was a heavy tobacco smoker and was treated for hyperlipemia. During the week preceding admission, the patient complained of fever (38 [degrees] C), increasing dyspnea, and dry cough. On physical examination, he was febrile (38.2 [degrees] C), the pulse rate was 120 beats per minute, and the blood pressure 90/45 mm Hg. Respiratory rate was 50 per minute. Dry rales were heard bilaterally. Laboratory examination results follow: hematocrit was 38.6 percent; hemoglobin, 12.9 g/dl; WBC count, 7.7 [multiplied by] [10.sup.9]/L with 6 percent band cells; platelet count, 164 [multiplied by] [10.sup.9]/L; prothrombin time, 65 percent of control and activated partial thromboplastin time, 30.4 s; bilirubin, 16 [mu]M/L; alkaline phosphatase, 35 U/L; aspartate aminotransferase and alanine aminotransferase, 450 and 537 U/L, respectively; lactate dehydrogenase, 2,103 U/L; chest x-ray, bilateral interstitial infiltrates; and arterial blood gases ([FIO.sub.2] = 0.4), pH 7.2, [PaCO.sub.2] 2.5 kPa, [PaO.sub.2] 8.0 kPa, oxygen saturation ([SaO.sub.2]) 88 percent, base excess--15 mmol/L.

[TABULAR DATA OMITTED]

Broad spectrum antibiotic therapy with amoxicillin/clavulanic acid and erythromycin was started. The next day, because of worsening hypoxemia and clinical signs of respiratory muscle fatigue, the patient was intubated and mechanical ventilation initiated. Bronchoalveolar lavage showed 14x[10.sup.4] cells/ml, 34 percent macrophages, 2 percent lymphocytes, 62 percent polymorphonuclear, 1 percent eosinophils, and 1 percent basophils. Blood and lavage cultures remained sterile. While receiving 100 percent [O.sub.2] with a PEEP of 5 cm [H.sub.2]O, arterial blood gases were pH 7.34, [PaCO.sub.2] 5.7 kPa, [PaO.sub.2] 9.88 kPa, and [SaO.sub.2] 91 percent. Peak inspiratory pressure (PIP) was 40 cm [H.sub.2]O. A mixed ventilatory mode combining high frequency jet and conventional ventilations was started the same day, allowing both a decrease in PIP (25 to 30 cm [H.sub.2]O) and a transiently better oxygenation ([FIO.sub.2] 0.55, [SaO.sub.2] 90 percent). The situation worsened over the next 6 days, however, requiring a progressive increase in [FIO.sub.2] to 1.0 with [SaO.sub.2] between 80 and 90 percent. As a complication of this severe hypoxemia, the patient had an inferior myocardial infarction (creatine kinase/creatine kinase-MB=769/120 U/L). A trial of nitric oxide (35 to 50 ppm) delivered via the inspiratory line was unsuccessful for increasing [PaO.sub.2]. As pulmonary arterial pressure was in the normal range, two tests with AB, 1 mg/kg intravenously during 1 h were performed, 24 h apart (Table 1). As both tests were beneficial to [SaO.sub.2] and well tolerated, a continuous infusion was administered, the dosage being adjusted (0.1 to 0.5 mg/kg/h) to maintain a [SaO.sub.2] [greater than or equal to] 85 percent. The AB was infused for a total of 115 h.

Figure 1 shows calculated shunt (Qs/QT) while the patient was ventilated with 100 percent [O.sub.2] during the AB infusion at different dosages. The only significant complications of ARDS were recurrent pneumothoraces requiring chest tube drainage. Otherwise, the patient progressed well and was extubated after 26 days. He presented a marked weakness for which a muscular biopsy and an electromyography were performed. The diagnosis was mild myogenic muscular atrophy without inflammation. There were no electrophysiologic signs of peripheral neuropathy. The patient improved and was discharged from the hospital after 42 days. Three months later, the patient walks freely without any paresthesia or dysesthesia.

DISCUSSION

This report confirms the efficacy of AB in improving refractory hypoxemia in ARDS. This effect is most probably a result of an improvement in ventilation/perfusion inequality, as has been shown in clinical studies,[5,8,9] in the absence of any ventilatory or significant hemodynamic variations. The dosage necessary to obtain a significant effect was 0.35 to 0.5 mg/kg/h, consistent with previous reports.[4,5]

There are three points of interest in this case report. First, it is, to our knowledge, the longest intravenous high dose AB treatment reported in a patient with ARDS. The AB was maintained because serial attempts to reduce it met with a significant worsening of hypoxemia, which had been, most certainly, in part responsible for the myocardial infarction.

Second, our main fear during AB infusion was the potential development of pulmonary arterial hypertension, which is thought to result from AB-induced vasoconstriction.[7] Continuous monitoring with a Swan-Ganz catheter, however, showed a maximal mean pulmonary arterial pressure of 25 mm Hg and no significant change in cardiac output. By comparison, in patients with ARDS, two studies have shown a significant albeit small increase in pulmonary artery pressure (PAP) during a short AB perfusion.[4,5] Conversely, Prost et al[6] have observed no such change in their patients. None of these authors measured significant modifications in cardiac output. Recently, Plaisance and Payen[10] have shown that the improvement in [PaO.sub.2] is not correlated with an increase in PAP.

Finally, peripheral neuropathy, another recognized complication of long-term AB treatment, usually occurs after several months of treatment,[1] and seems to be accentuated by high doses of AB.[3] When our patient awakened, signs of muscular weakness became apparent, but without paresthesia or dysesthesia. The differential diagnoses of this condition included the effects of long-term immobilization, treatment with neuromuscular-blocking drugs,[11] the neurologic complications of ARDS[12] and the prolonged treatment with AB. A muscular biopsy and an electromyography were performed, which allowed a diagnosis of myogenic atrophy, without peripheral neuropathy, and the clinical recovery confirmed the diagnosis.

In conclusion, AB acutely increased [PaO.sub.2] and decreased QS/QT in a patient with ARDS and severe refractory hypoxemia. Furthermore, these benefits were maintained during a prolonged course (115 h) until the improvement of ARDS occurred. No side effects such as pulmonary arterial hypertension or peripheral neuropathy were observed. Almitrine bismesilate could be an effective treatment of ARDS-induced hypoxemia, particularly in a subgroup of patients without pulmonary arterial hypertension but with severe hypoxemia where high [FIO.sub.2] is both insufficient and potentially deleterious.

REFERENCES

[1] Voisin C, Howard P, Ansquer J. Almitrine bismesylate: a long-term placebo-controlled double-blind study in COAD. Vectarion international multicentre study group. Bull Eur Physiopathol Respir 1987; 23(suppl 11):169-82

[2] Evans T, Tweney J, Waterhouse J, Nichol J, Suggett A, Howard P. Almitrine bismesylate and oxygen therapy in hypoxic cor pulmonale. Thorax 1990; 45:16-21

[3] Watanabe S, Kanner R, Cutillo A, Menlove RL, Bachand RT, Szalkowski MB. Long-term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140:1269-73

[4] Reyes A, Lopez-Messa J, Alonso P. Almitrine in acute respiratory failure: effects on pulmonary gas exchange and circulation. Chest 1987; 91:388-93

[5] Reyes A, Roca J, Rodriguez-Roisin R, Torres A, Ussetti P, Wagner P. Effect of almitrine on ventilation-perfusion distribution in adult respiratory distress syndrome. Am Rev Respir Dis 1988; 137:1062-67

[6] Prost J, Desche P, Jardin F, Margairaz A. Comparison of the effects of intravenous almitrine and positive-end-expiratory pressure on pulmonary gas exchange in adult respiratory distress syndrome. Eur Respir J 1991; 4:683-87

[7] Dull W, Polu J, Sadoul P. The pulmonary haemodynamic effects of almitrine infusion in men with chronic hypercapnia. Clin Sci 1983; 64:25-31

[8] Rigaud D, Dubois F, Boutet JCB, Verain A, Paramelle B. Effets de l'almitrine sur la distribution isotopique de la ventilation et de la perfusion regionales chez l'insuffisant respiratoire chronique. Rev Mal Respir 1980; 8:605-16

[9] Evrard Y. Bismesilate d'almitrine et rapports ventilation-perfusion. Rev Mal Respir 1985; 2(suppl 1):S17-22

[10] Plaisance P, Payen D. Role of almitrine-induced pulmonary arterial pressure (PAP) increase on gas exchange improvement. Int Care Med 1992; 18:S111

[11] Segredo V, Calwell J, Matthay M, Sharma M, Gruenke L, Miller R. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992; 327:524-28

[12] Witt N, Zochodne D, Bolton C, Grand'Maison F, Wells G, Young B, et al. Peripheral nerve function in sepsis and multiple organ failure. Chest 1991; 99:176-84

COPYRIGHT 1994 American College of Chest Physicians
COPYRIGHT 2004 Gale Group

Return to Short QT syndrome
Home Contact Resources Exchange Links ebay